MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2023 International Congress

    Investigating glutamate toxicity associated to Park2 mutations in pre-clinical models of Parkinson’s Disease

    I. Trezzi, M. Regoni, M. Magni, M. Schröter, A. Buccino, D. Lopez, G. Faustini, L. Murro, F. Biella, E. Frattini, R. Silipigni, M. Passafaro, A. Bellucci, M. Bortolozzi, J. Sassone, A. Di Fonzo (Milan, Italy)

    Objective: To generate and characterize induced pluripotent stem cells (iPSCs)-derived in vitro cellular models of Autosomal Recessive Juvenile Parkinsonism (ARJP) carrying Park2 mutations with a…
  • 2023 International Congress

    Meige Syndrome Following COVID Infection

    E. Girouard, A. Levy (Montréal, Canada)

    Objective: This study aimed to describe the case of a 61-year-old woman who developed Meige syndrome following a COVID infection, to review the different post-COVID…
  • 2023 International Congress

    The Comorbidity and Comedication Profiles of Patients with Progressive Supranuclear Palsy in Two German, Multicenter Cohorts: A Systematic Cross-Sectional Analysis

    S. Greten, F. Wegner, O. Krause, J. Heck, GU. Höglinger, M. Klietz (Hannover, Germany)

    Objective: To investigate the pattern of comorbidities and comedications in PSP patients compared to age-matched controls. Background: Although progressive supranuclear palsy (PSP) is usually diagnosed…
  • 2023 International Congress

    Multi-stakeholder focus group study to develop recommendations of ways to improve treatment burden and capacity in Parkinson’s disease

    QY. Tan, S. Fraser, H. Roberts, K. Ibrahim (Southampton, United Kingdom)

    Objective: To develop recommendations of ways to improve treatment burden and capacity in Parkinson’s disease (PD) Background: Our research has identified potentially modifiable factors of…
  • 2023 International Congress

    Neurogenic Orthostatic Hypotension in Parkinson’s Disease: Is there a role for Locus Coeruleus Magnetic Resonance Imaging?

    G. Palermo, G. Bellini, A. Galgani, F. Lombardo, N. Martini, R. Morganti, D. Paoli, S. de Cori, FS. Giorgi, R. Ceravolo (Pisa, Italy)

    Objective: To test whether degeneration of the Locus Coeruleus (LC) is associated with Orthostatic Hypotension (OH) in Parkinson’s disease (PD).To test whether degeneration of the…
  • 2023 International Congress

    Opicapone versus entacapone: Head-to-head comparison of Healthcare Resource Utilisation in COMT-I naïve People with Parkinson’s

    G. Harrison-Jones, L. Marston, F. Morgante, K R. Chaudhuri, G. Castilla-Fernández, V. Di Foggia (Windsor, United Kingdom)

    Objective: In this retrospective cohort study, we assessed healthcare resource utilisation (HCRU) outcomes in People with Parkinson’s (PwP) naïve to Catechol-O-methyl transferase (COMT) inhibition via…
  • 2023 International Congress

    Levodopa-induced dyskinesia and Huntington’s chorea: link to current motor control theories

    JF. Daneault, Y. Liu, J. Miranda, C. Duval, M. Chen, S. Lee (Newark, USA)

    Objective: Determine if there is a motor control hypothesis that could explain movement kinematics of Huntington’s disease (HD) chorea and Parkinson’s disease (PD) levodopa-induced dyskinesia…
  • 2023 International Congress

    Istradefylline effect on Parkinson’s Disease Tremor, Motor symptoms and non-Motor symptoms.

    K. Chandrakumar, B. Wilmarth, B. Nagle, G. Di Maria, O. Gonul, L. Lovelace, E. Waldon, K. Getchell, Y. Torres-Yaghi, F. Pagan (Washington, USA)

    Objective: Istradefylline is FDA approved for use in patients with PD treated with carbidopa-levodopa to reduce off time. GUH Movement Disorder Group has observed that…
  • 2023 International Congress

    Progression of the Clinical Features of Progressive Supranuclear Palsy-Richardson Syndrome in Early and Advanced Stages

    T. Xie, C. Liao, L. Golbe (Chicago, USA)

    Objective: We sought to evaluate PSP-Richardson syndrome (PSP-RS) for uniformity of progression over nearly the entire disease course. Rather than comparing scores to the simple…
  • 2023 International Congress

    Honey prevented MPTP-induced oxidative stress, neuroinflammation and gliosis in adult male Swiss mice.

    F. Sulaimon, R. Ibiyeye, A. Imam, A. Imam, M. Ajao (Ilorin, Nigeria)

    Objective: To investigate the neuroprotective role of honey against oxidative stress and neuroinflammation induced by MPTP in adult male Swiss mice. Background: Oxidative stress and…
  • « Previous Page
  • 1
  • …
  • 134
  • 135
  • 136
  • 137
  • 138
  • …
  • 186
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley